Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms
Latest Information Update: 31 Jan 2025
Price :
$35 *
At a glance
- Drugs Bimekizumab (Primary) ; Ixekizumab (Primary) ; Secukinumab (Primary)
- Indications Depression
- Focus Pharmacodynamics
- Acronyms ELATE
- 27 Jan 2025 New trial record